7896 Federal Register / Vol. 72, No. 34 / Wednesday, February 21, 2007 / Notices 

non-endocrine tumors and 

malignancies. 

The inventor is continuing work on 

the development and functional 

characterization of the PDE11A and its 

variants in relation to iMAD and other 

tumors and malignancies of the 

endocrine system. 

Competitive Advantage of Our 

Technology 

Cushing Syndrome occurs in 5 to 10 

per 15 million every year and 27,000 

new cases of endocrine tumors are 

diagnosed every year. Our technology 

identifies a functional role of PDE11A in 

a new form of Cushing Syndrome and 

its possible role in endocrine tumors 

and/or other cancers. PDE inhibitors 

have been successfully used in the 

treatment of erectile dysfunction. 

Currently, there are three products in 

the market, which inhibit the different 

forms of PDEs for the treatment of 

erectile dysfunction: Sildeafil (Viagra), 

Vardenafil (Levitra) and Tadalafil 

(Cialis) manufactured by Pfizer, 

GlaxoSmithkline/Bayer/ScheringPlough and Lily Icos respectively. 

Among the marketed PDE inhibitors, 

Cialis targets PDE11A and PDE5A. 

Most interestingly, Cialis has no 

known effects on the adrenal gland and 

endocrine system and no PDE gene has 

ever been reported to be associated with 

endocrine or other human tumor 

development. Our invention of the 

variants of PDE11A genes and 

subsequent new protein PDE11A4 from 

one of the genetic variants have opened 

up the possibility of the development of 

new drugs for iMAD, adrenal 

hyperplasia and other endocrine tumors 

and malignancies targeting these 

proteins. 

The three marketed PDE inhibitors 

mentioned above have exceeded 

individual worldwide sales figures of 1 

billion dollars each in 2007 and have 

been projected to grow steadily in the 

next few years. Additionally, the 

endocrine drug market has been 

projected to grow to more than 40 

billion dollars in the next 5 years. New 

PDE inhibitors and the ones in the 

market are all in clinical trials for 

several diseases such as erectile 

dysfunction, neurological diseases and 

cardiovascular diseases. 

Our technology suggests that drugs 

that modulate PDE function can be used 

in treating iMAD, a rare genetic form of 

Cushing Syndrome with fatal 

implications in children. The new 

PDE11A gene variants that have been 

identified have diagnostic and 

therapeutic implications. PCR-based 

diagnostic tools can be developed to 

diagnose iMAD and novel antagonists 

targeting these PDE11A variants can be 

identified and developed as drugs. 

Patent Estate 

This technology consists of U.S. 

Provisional Applications Serial No. 60/ 

761,446 entitled ‘‘PDE11A mutations in 

Adrenal Diseases’’ filed January 24, 

2007. A PCT application has also been 

filed. 

Next Step: Teleconference 

There will be a teleconference where 

the principal investigator will explain 

this technology. Licensing and 

collaborative research opportunities will 

also be discussed. If you are interested 

in participating in this teleconference 

please call or e-mail Mojdeh Bahar; 

(301) 435–2950; baharm@mail.nih.gov. 

OTT will then e-mail you the date, time 

and number for the teleconference. 

Dated: February 13, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–2884 Filed 2–20–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Amended Notice 

of Meeting 

Notice is hereby given of a change and 

additional information for the meeting 

of the Advisory Committee to the 

Director, NIH, February 21, 2007, 2:30 to 

4 p.m., National Institutes of Health, 

9000 Rockville Pike, Bethesda, MD 

20892 (Telephone Conference Call) 

which was published in the Federal 

Register on February 8, 2007, 72 FR 

5982. 

The meeting will be held from 2:30 

p.m. to 4:30 p.m. Also, individuals 

interested in attending the meeting must 

contact Dr. Penny W. Burgoon for 

telephone number and pass code. The 

meeting is open to the public. 

Dated: February 9, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–763 Filed 2–20–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel, 

Research Demonstration and Dissemination 

Projects (R18). 

Date: March 6, 2007. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Patricia A. Haggerty, PhD, 

Scientific Review Administrator, Review 

Branch/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7194, Bethesda, MD 20892–7924, 301–435–

0288, haggertp@nhibi.nih.gob. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: February 9, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–761 Filed 2–20–07; 8:45 am] 

BILLING CODE 4140–07–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 


rmajette on PROD1PC67 with NOTICES
Federal Register / Vol. 72, No. 34 / Wednesday, February 21, 2007 / Notices 7897 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel, MOUSE Repository RFA. 

Date: March 8, 2007. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Lombardy, 2019 Pennsylvania 

Ave., NW., Washington, DC 20006. 

Contact Person: Ken D. Nakamura, PhD, 

Scientific Review Administrator, Office of 

Scientific Review, National Human Genome 

Research Institute, National Institutes of 

Health, Bethesda, MD 20892, 301–402–0838. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel, Sequencing Technology RFA. 

Date: March 15–16, 2007. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Rouge, 1315 16th Street, NW., 

Washington, DC 20036. 

Contact Person: Ken D. Nakamura, PhD, 

Scientific Review Administrator, Office of 

Scientific Review, National Human Genome 

Research Institute, National Institutes of 

Health, Bethesda, MD 20892, 301–402–0838. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: February 13, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–755 Filed 2–20–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Child Health and 

Human Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Maintenance and 

Operation of a Chemical Synthesis Facility. 

Date: February 27, 2007. 

Time: 12 p.m. to 1:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6100 

Executive Boulevard, Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Hameed Khan, PhD, 

Scientific Review Administrator, Division of 

Scientific Review, National Institute of Child 

Health and Human Development, NIH, 6100 

Executive Blvd., Room 5B01, Bethesda, MD 

20892, (301) 435–6902, khanh@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: February 12, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–751 Filed 2–20–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institutes of Child Health and 

Human Development; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Nutrient Restriction: 

Placental and Fetal Brain and Renal 

Outcomes and Mechanisms. 

Date: February 21, 2007. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6100 

Executive Blvd., 5B01, Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Gopal M. Bhatnagar, PhD., 

Scientific Review Administrator, National 

Institute of Child Health and Human 

Development, National Institutes of Health, 

6100 Bldg., Rm. 5B01, Rockville, MD 20852, 

(301) 435–6889, bhatnagg@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Child Health and Human Development Initial 

Review Group, Developmental Biology 

Subcommittee. 

Date: February 26–27, 2007. 

Time: 8 a.m. to 5 pm. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel at Pentagon City, 

1250 South Hayes Street, Arlington, VA 

22202. 

Contact Person: Norman Chang, PhD., 

Scientific Review Administrator, Division of 

Scientific Review, National Institute of Child 

Health and Human Development, NIH, 6100 

Executive Blvd., Room 5B01, Bethesda, MD 

20892, (301) 496–1485, 

changn@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Child Health and Human Development Initial 

Review Group; Biobehavioral and Behavioral 

Sciences Subcommittee. 

Date: February 27–28, 2007. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott at Metro Center, 775 12th 

Street, NW., Washington, DC 20005. 

Contact Person: Marita R. Hopmann, PhD., 

Scientific Review Administrator, Division of 

Scientific Review, National Institute of Child 

Health and Human Development, NIH, 6100 

Executive Boulevard, Room 5B01, Bethesda, 

MD 20892, (301) 435–6911, 

hopmannm@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic 

Assistance Program Nos. 93.864, 

Population Research; 93.865, Research 

for Mothers and Children; 93.929, 

Center for Medical Rehabilitation 

Research; 93.209, Contraception and 


rmajette on PROD1PC67 with NOTICES